Abstract
During the COVID-19 pandemic, the World Health Organization updated guidelines for travel measure implementation to recommend consideration of a region’s specific epidemiological, health system, and socioeconomic context. Region-specific data, analysis, and models are needed to support risk assessment frameworks based on these updated guidelines. During the pandemic, the Canadian province of Newfoundland and Labrador (NL) implemented travel measures that applied to non-residents of NL, and NL residents that worked outside the province. We found that during the pandemic travel to NL decreased by 82%, and the percentage of travelers arriving from Québec decreased from 14% to 4%. Daily travel-related cases are predicted by generalized linear models that consider the product of travel volume and prevalence proportion at travelers’ jurisdictions of origin (Canada), and travel volume only (international). A mechanistic model, formulated independently of the travel-related case data, predicts travel-related cases reasonably well. During the pandemic in NL, importation modelling was well-supported by daily public reporting of travel-related cases. Travel-related case data, and daily travel volume data, are needed to support the development and refinement of importation models to inform decisions regarding travel measure implementation during a public health emergency.
Competing Interest Statement
AH was a member of the Newfoundland and Labrador Predictive Analytics modelling team and previously received funding from the Newfoundland and Labrador Department of Health and Community Services.
Funding Statement
All authors were supported by funding from Mathematics for Public Health (560523-2020), the One Health Modelling Network for Emerging Infections (560520-2020), and by the Emerging Infectious Disease Modelling Consortium funded by the Natural Sciences and Engineering Council of Canada. AH and JA are supported by the Canadian Network for Modelling Infectious Diseases (560516-2020)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Health Research Ethics Board of Newfoundland and Labrador gave ethical approval for this work (reference number 2021.013)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Revised in response to reviewer comments. General linear modelling redone as generalized linear models. Figure 4 shows the model fit as daily, rather than monthly, and is easier to interpret. The models are better documented as text has been moved into the main text from the Supplementary Information.
Data Availability
Data requiring ethics approval can be requested from the Newfoundland and Labrador Health Services, Digital Health. All publicly available data are archived online.
